摘要
目的研究合并代谢综合征（MS）的精神分裂症患者予吡格列酮治疗后认知功能变化。方法40例合并MS的慢性精神分裂症患者随机分为两组，分别予吡格列酮15mg／d（吡格列酮组）及安慰剂（安慰剂组）双盲治疗12周，在基线、12周末进行血压、体重、血糖、血脂等代谢指标评定，以及PANSS、TESS、RBANS量表评定。结果吡咯列酮组与安慰剂组基线时高密度脂蛋白（HDL）差异有统计学意义（P〈0．05），治疗12周末仅舒张压的差异有统计学意义（P〈0．05）；治疗12周末，吡格列酮组糖化血红蛋白、甘油三酯、HDI，均优于基线时，安慰剂组HDL优于基线时，差异均有统计学意义（P〈0．05）。PANSS、TESS量表的评分在组内和组间比较差异均无统计学意义（P〉0．05）。治疗12周末，吡格列酮组视觉空间结构因子分较安慰剂组高，差异有统计学意义（P〈0．05）。吡格列酮组RBANS总分及即刻记忆、延迟回忆因子分较组内基线高，安慰剂组即刻记忆、延迟回忆因子分较组内基线高，差异均有统计学意义（P〈0．05）。结论吡格列酮治疗合并代谢综合征的精神分裂症患者，不仅可以改善其代谢状态，而且可以改善其认知功能。
Objective To explore the effect of pioglitazone treatment on cognitive function of schizophrenia patients with metabolic syndrome （MS）. Methods The study randomly divided 40 chronic schizophrenia patients with MS into two groups. One group was treated with pioglitazone 15 mg qd （pio- glitazone group）, the other was treated with placebo （placebo group）. The two groups were treated with the drugs in a double--blind fashion for 12 weeks. At the baseline and the time point of 12 weeks after treatment, the Repeatable Battery was used for the Assessment of Neuropsychological Status （RBANS） and a series physiobiochemisty indexes. In addition, the PANSS scales and TESS scales were implemen- ted at baseline, the time points of 12th weekend. Results At baseline, there is a significant difference in the index of HDL between pioglitazone and placebo （P〈 0.05）, at the time point of 12th weekend. There was only the index of DP being significant between the two groups （P〈0.05）. After treated with drugs for 12 weeks, pioglitazone group showed improvement in indexes of HbAlc, TG, and HDL signif- icantly than before （P〈0.05）. In contrast, there is a significant change on the index of HDL （P〈0.05） in placebo group. There was no statistic significance between or in the two groups in PANSS and TESS scores. At the time point of 12th week after treatment, tile pioglitazone group had a significant change from baseline in scores on visual--spatial structure factor, immediate memory, delayed recall fac- tors and the total scores of RBANS （P〈0.05）. Placebo group had a significant changes from baseline in the scores on visual--spatial structure factor and immediate memory （P〈0.05）. Conclusions The metabolic status and cognitive function can be improved with pioglitazone treatment in the schizophrenia patients with MS.
出处
《神经疾病与精神卫生》
2013年第2期121-124,共4页
Journal of Neuroscience and Mental Health
基金
上海市卫生局科研课题项目（2009097）
国家自然科学基金（81171272）
上海市公共卫生优秀学科带头人培养计划（GWDTR201227）
卫生行业科研专项（201002003）
关键词
精神分裂症
代谢综合征
认知功能
吡咯列酮
Schizophrenia
Metabolic syndrome
Cognitive function
Pioglitazone
